Joseph Pantginis an analyst with Roth Capital Partners said it would have taken five to ten years before Geron's lead stem cell product reached the market.
This was a classic business calculation, you have two blockbuster programs but only enough money for one, so you choose the one that is further along.
Celgene, Pfizer and Teva Pharm. are in stem cell research, small time. Partnering with Geron would make them big time and they have the money to fund the research.
The share price is worrying me. It could go below a dollar. Only good news from the four Phase II trials will raise the share price. If by the end of 2012 the results from the 4 Phase II trials are anything but outstanding I will sell most of my shares. For now any move over $2 I will sell some shares and sell a few covered calls.
I put a lot of time and money into Geron, believing [and still do] in the stem cell program, now there is very little reason for me to hold a large position in this company.
Good luck in this rigged casino,
No comments:
Post a Comment